Prof. Nicolaas Lumen
(28 June 2017)
Currently, the gold standards in prostate cancer diagnosis are a PSA test and a digital rectal examination (DRE). Because of the low performance of these diagnostic methods, a lot of patients will undergo an unnecessary prostate biopsy. The result: a lot of insignificant prostate cancer that should never be found.
We need a biomarker test to avoid unnecessary biopsies, to avoid overdiagnosis, and to avoid overtreatment